Academic drug programs often begin with promising data and a clear therapeutic idea. The next challenge is translating that discovery into a development program that can support an Investigational New Drug (IND) filing, a transition where early missteps can introduce delays that are difficult and costly to recover from.
Academic teams frequently enter this stage with strong scientific insight but limited exposure to the time commitment, cross-functional planning, and coordination required to move a drug candidate into clinical trials. Industry analyses estimate that advancing a product from the start of clinical development through approval takes an average of 8.2 years, with a median of 7.2 years.1 Long before that point, critical development decisions begin to shape whether a program will progress efficiently or stall under the weight of rework and unmet requirements. Understanding where academic discovery gives way to development reality can help academic innovators plan more effectively and avoid costly and time-intensive setbacks.
Academic Programs vs Pharmaceutical Companies
In large pharmaceutical organizations, early research and development functions operate within the same system. Scientists generating proof-of-concept data can coordinate with regulatory affairs, clinical, quality, and manufacturing teams that already understand what will be required for an IND submission. Development activities are typically aligned to a defined regulatory endpoint, with each function contributing to a cohesive plan designed to support that filing.
Academic programs often reach this inflection point without corresponding infrastructure in place. A research lab may produce strong early data and secure funding, but the work has typically been designed to answer scientific questions rather than support IND-enabling development. In many cases, progress is driven by discrete milestones tied to funding, publication, or grant cycles rather than a fully mapped path to IND. The challenge for many academic innovators is learning how to convert a promising research result into a structured program that can withstand regulatory, technical, and operational expectations. Without that shift, each step advances a near-term goal but will not always build toward a cohesive, IND-ready program.
The Key Steps Between Academic Discovery and IND Filing
Each stage of moving a discovery from the laboratory toward IND filing introduces requirements that must build on one another. When those requirements are not aligned early, gaps often surface later as rework, added studies, or delays that can extend timelines and strain limited resources. Designing early development work with the end goal in mind, rather than optimizing for individual milestones, helps ensure that each step contributes meaningfully to IND readiness.
While every program follows its own path depending on the therapeutic area, dosage form, and available data, most academic drug programs move through multiple common phases:
- Proof of concept and early translational assessment: Academic teams establish the initial evidence that a compound or therapeutic approach has biological activity and potential clinical relevance; at this stage, the focus is often on demonstrating that the concept works in relevant models and that the underlying mechanism is well understood
- Formulation and analytical development: Early work begins to define how the drug candidate can be formulated and how its quality will be measured; analytical methods and formulation strategies developed at this stage should be selected with later validation and manufacturing transfer in mind
- Stability work and clinical supply planning: Teams begin evaluating stability and preparing for the production of material to support future studies; these efforts help determine whether the candidate can maintain potency and quality long enough for clinical use and whether the proposed product can realistically support the intended clinical timeline
- Preclinical and regulatory planning: IND preparation requires a defined strategy that connects preclinical data, safety assessment, and the intended clinical plan; for many programs, this stage includes preparing for early FDA engagement, such as a pre-IND meeting, before critical development decisions are locked in
- IND-enabling package assembly: The final stage involves organizing the technical, manufacturing, and regulatory documentation needed to support an IND submission, including data from formulation work, analytical methods, manufacturing activities, and preclinical studies that demonstrate readiness to begin human trials; for first-time academic teams, this is often the point at which the required level of detail, documentation, and coordination proves greater than expected
Where Academic Discoveries Meet Development Reality
As academic programs move from proof of concept toward IND preparation, many teams encounter the same development challenges. A promising candidate does not move toward the clinic on scientific merit alone. It moves forward when the data package, product strategy, manufacturing approach, and regulatory plan are aligned well enough to support the next decision point. When they are not, teams often face rework that could have been avoided with earlier development planning, sometimes setting programs back months or more.
Pitfall #1: Building Around Data That Cannot Carry Forward
Early analytical methods that produce useful data in a research environment may later prove difficult to validate. Likewise, formulations may seem suitable in early experiments but reveal weaknesses when stability testing becomes more rigorous. When these gaps surface late in development, teams may need to redesign assays, reformulate the product, or repeat studies, adding months of rework.
Pitfall #2: Treating Each Milestone as a Stand-Alone Task
Academic programs often focus on the next milestone needed to secure funding or publish results. While this near-term focus is often necessary, it can result in development activities being planned in isolation rather than as part of an integrated path to IND. Activities such as analytical development, formulation work, and stability testing should be designed with the eventual IND filing in mind. Programs move more efficiently when teams work backward from the intended filing goal and map the data, studies, and manufacturing steps required to support it, instead of advancing each milestone independently without clear alignment to the end objective.
Pitfall #3: Underestimating What cGMP Readiness Requires
Once a program prepares to produce clinical batches, analytical methods must be ready for validation, formulations must be defined well enough for manufacturing transfer, and stability data must support the proposed clinical use period. If these elements are not addressed early enough, the manufacturing site may not be able to initiate or complete clinical batch production, and IND timelines may need to shift to accommodate additional development work before the program can proceed.
Pitfall #4: Weak Sequencing Creates Avoidable Bottlenecks
Drug development activities are tightly connected, but teams sometimes identify a target FDA filing date without fully mapping the sequence of work required to reach it. When prerequisite data or manufacturing steps fall behind schedule, timelines compress quickly and critical milestones must move. Clear sequencing of development activities helps ensure that each step produces the data needed for the next.
The Value of an Experienced Partner
For academic innovators, the moment a discovery begins moving toward IND preparation is often the first time the program must operate like a full drug development effort rather than a research project. Unless strategy is strong, small missteps can quickly compound into delays that push an IND timeline back by months and, in some cases, jeopardize the program’s ability to progress at all.
An experienced partner helps bring structure to that transition, not just by executing discrete tasks, but by anticipating where misalignment, rework, or sequencing gaps are most likely to occur and addressing them early. At Kiel Laboratories, we work alongside academic teams to map the work required for IND readiness, align development activities to a clear regulatory path, and ensure that each activity supports the next stage of the program. By aligning scientific insight with practical development planning, Kiel helps innovators turn promising discoveries into programs that are better prepared for regulatory review and clinical progress.
If your team is preparing to move a discovery toward IND filing, connect with Kiel’s experts.
Reference
- Laurent, A. (2025, November 18). The Drug Development Timeline: Why It Takes Over 10 Years. IntuitionLabs. https://intuitionlabs.ai/articles/drug-development-timeline-explained